These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 21057378)

  • 21. Clinical outcome of elderly patients with metastatic colorectal cancer treated with FOLFOXIRI versus FOLFIRI: Subgroup analysis of a randomized phase III trial from the Hellenic Oncology Research Group (HORG).
    Vamvakas L; Athanasiadis A; Karampeazis A; Kakolyris S; Polyzos A; Kouroussis Ch; Ziras N; Kalbakis K; Georgoulias V; Souglakos J
    Crit Rev Oncol Hematol; 2010 Oct; 76(1):61-70. PubMed ID: 19729318
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical and economic evaluation of first-line therapy with FOLFIRI or modified FOLFOX6 for metastatic colorectal cancer.
    Ajima H; Ogata H; Fujita K; Miwa K; Sunakawa Y; Mizuno K; Ishida H; Yamashita K; Nakayama H; Kawara K; Takahashi H; Sasaki Y
    Jpn J Clin Oncol; 2010 Jul; 40(7):634-8. PubMed ID: 20587616
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Chemotherapy of metastatic colorectal cancer: fluorouracil plus folinic acid and irinotecan or oxaliplatin.
    Prescrire Int; 2005 Dec; 14(80):230-3. PubMed ID: 16400749
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Outcome of metastatic colorectal cancer: analysis of a consecutive series of 229 patients. The impact of a multidisciplinary approach.
    Sperti E; Faggiuolo R; Gerbino A; Magnino A; Muratore A; Ortega C; Ferraris R; Leone F; Capussotti L; Aglietta M
    Dis Colon Rectum; 2006 Oct; 49(10):1596-601. PubMed ID: 16988853
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Intensive systemic chemotherapy combined with surgery for metastatic colorectal cancer: results of a phase II study.
    Taïeb J; Artru P; Paye F; Louvet C; Perez N; André T; Gayet B; Hebbar M; Goebel FM; Tournigand C; Parc R; de Gramont A
    J Clin Oncol; 2005 Jan; 23(3):502-9. PubMed ID: 15659495
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Gene expression of ferredoxin reductase predicts outcome in patients with metastatic colorectal cancer treated by 5-fluorouracil plus leucovorin.
    Ichikawa W; Ooyama A; Toda E; Sugimoto Y; Oka T; Takahashi T; Shimizu M; Sasaki Y; Hirayama R
    Cancer Chemother Pharmacol; 2006 Dec; 58(6):794-801. PubMed ID: 16528528
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase III trial comparing 4-day chronomodulated therapy versus 2-day conventional delivery of fluorouracil, leucovorin, and oxaliplatin as first-line chemotherapy of metastatic colorectal cancer: the European Organisation for Research and Treatment of Cancer Chronotherapy Group.
    Giacchetti S; Bjarnason G; Garufi C; Genet D; Iacobelli S; Tampellini M; Smaaland R; Focan C; Coudert B; Humblet Y; Canon JL; Adenis A; Lo Re G; Carvalho C; Schueller J; Anciaux N; Lentz MA; Baron B; Gorlia T; Lévi F;
    J Clin Oncol; 2006 Aug; 24(22):3562-9. PubMed ID: 16877722
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [A review of FOLFOXIRI chemotherapy for the 1st line treatment of metastatic colorectal cancer].
    Kawakami H; Satoh T; Nakagawa K
    Nihon Rinsho; 2011 Apr; 69 Suppl 3():439-45. PubMed ID: 22214001
    [No Abstract]   [Full Text] [Related]  

  • 29. Neutropaenia as a prognostic factor in metastatic colorectal cancer patients undergoing chemotherapy with first-line FOLFOX.
    Shitara K; Matsuo K; Takahari D; Yokota T; Inaba Y; Yamaura H; Sato Y; Najima M; Ura T; Muro K
    Eur J Cancer; 2009 Jul; 45(10):1757-63. PubMed ID: 19217278
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The combination of ERCC1 and XRCC1 gene polymorphisms better predicts clinical outcome to oxaliplatin-based chemotherapy in metastatic colorectal cancer.
    Liang J; Jiang T; Yao RY; Liu ZM; Lv HY; Qi WW
    Cancer Chemother Pharmacol; 2010 Aug; 66(3):493-500. PubMed ID: 19960344
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Oxaliplatin in patients with metastatic colorectal cancer: efficacy and pharmacokinetics parameters.
    Burz C; Berindan-Neagoe I; Balacescu O; Todor N; Pelau D; Floares C; Kacso G; Tanaselia C; Ursu M; Vlase L; Leucuta SE; Cristea V; Irimie A
    J BUON; 2010; 15(2):263-9. PubMed ID: 20658719
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hepatic arterial infusion chemotherapy using fluorouracil followed by systemic therapy using oxaliplatin plus fluorouracil and leucovorin for patients with unresectable liver metastases from colorectal cancer.
    Seki H; Ozaki T; Shiina M
    Cardiovasc Intervent Radiol; 2009 Jul; 32(4):679-86. PubMed ID: 19296157
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Transcription factor-binding sites in the thymidylate synthase gene: predictors of outcome in patients with metastatic colorectal cancer treated with 5-fluorouracil and oxaliplatin?
    Paré L; Marcuello E; Altés A; del Rio E; Sedano L; Barnadas A; Baiget M
    Pharmacogenomics J; 2008 Oct; 8(5):315-20. PubMed ID: 17684476
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Modified FOLFOX6(mFOLFOX6)in metastatic colorectal carcinoma patients with poor performance status].
    Nishi T; Hamamoto Y; Uemoto J; Onodera K; Warita E; Yamanaka Y
    Gan To Kagaku Ryoho; 2012 Dec; 39(13):2557-60. PubMed ID: 23235179
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Which gene is a dominant predictor of response during FOLFOX chemotherapy for the treatment of metastatic colorectal cancer, the MTHFR or XRCC1 gene?
    Suh KW; Kim JH; Kim DY; Kim YB; Lee C; Choi S
    Ann Surg Oncol; 2006 Nov; 13(11):1379-85. PubMed ID: 17009149
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase III trial of FOLFOX plus bevacizumab or cediranib (AZD2171) as first-line treatment of patients with metastatic colorectal cancer: HORIZON III.
    Robertson JD; Botwood NA; Rothenberg ML; Schmoll HJ
    Clin Colorectal Cancer; 2009 Jan; 8(1):59-60. PubMed ID: 19203899
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Very low prevalence of XPD K751Q polymorphism and its association with XPD expression and outcomes of FOLFOX-4 treatment in Asian patients with colorectal carcinoma.
    Lai JI; Tzeng CH; Chen PM; Lin JK; Lin TC; Chen WS; Jiang JK; Wang HS; Wang WS
    Cancer Sci; 2009 Jul; 100(7):1261-6. PubMed ID: 19432884
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Role of microsatellite instability in the management of colorectal cancers.
    Buecher B; Cacheux W; Rouleau E; Dieumegard B; Mitry E; Lièvre A
    Dig Liver Dis; 2013 Jun; 45(6):441-9. PubMed ID: 23195666
    [TBL] [Abstract][Full Text] [Related]  

  • 39. AGXT and ERCC2 polymorphisms are associated with clinical outcome in metastatic colorectal cancer patients treated with 5-FU/oxaliplatin.
    Kjersem JB; Thomsen M; Guren T; Hamfjord J; Carlsson G; Gustavsson B; Ikdahl T; Indrebø G; Pfeiffer P; Lingjærde O; Tveit KM; Wettergren Y; Kure EH
    Pharmacogenomics J; 2016 Jun; 16(3):272-9. PubMed ID: 26261061
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Correlation between TBARS levels and glycolytic enzymes: the importance to the initial evaluation of clinical outcome of colorectal cancer patients.
    Farias IL; Farias JG; Rossato L; Araújo MC; Chiesa J; Morsh V; Schetinger MR
    Biomed Pharmacother; 2011 Sep; 65(6):395-400. PubMed ID: 21715128
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.